RE:RE:Safety/tolerability profile CZO mentioned that it also combined avenanthramide with one of its newer PGX carriers with promising results. The current pill trial may be a building block to greater things as PGX also reaches the decision point for mass industrialization. A recent paper by another group combined yeast beta glucan with avenanthramide with interesting results. CZO has also been working with the Angiogenesis Foundation on CZO's beta glucan and avenanthramide and Gilles called the results a home run for wound healing. Could that benefit a cardiovascular drug? Could the avenanthramide pill be used with the oat beta glucan chewy product? Who knows... This was also mentioned by the Angiogenesis Foundation:
August 2021:
“Endothelial cell stimulation is a hallmark of, and a requirement for, wound healing,” commented Dr. Vincent W. Li, Chief Scientific Officer of the Angiogenesis Foundation. “Given that Ceapro products have demonstrated in vitro activity that may impact healing at the cellular level, we expect to further characterize this biological activity using well-established in vivo models and assess their potential applications to a variety of functional health benefits. These benefits include tissue regeneration and repair as well as disease conditions such as COVID-19 and post-COVID-19, which are associated with severe blood vessel damage leading to thrombosis in the lungs and other organs. We believe this has the potential to address a root cause of such complications.”